Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

Amgen

Status: Enrolling

Conditions: Non-Small Cell Lung Cancer

Treatments: Drug: Sotorasib

Study type: Observational

Funder types: Industry

Identifiers

NCT07143513

20240175

Details and patient eligibility

About

The primary objective of this study is to characterize the safety profile of sotorasib.

Enrollment: 115 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult (≥ 18 years) as of the index date.
• KRAS p.G12C-mutated locally advanced or metastatic NSCLC.
• Received at least 1 dose of sotorasib.
• Receipt of at least 1 prior systemic therapy before use of sotorasib.
• Obtained ICF, if required.

Exclusion criteria

• Documentation of being a non-Chinese ethnicity.

Trial design

115 participants in 1 patient group

Chinese Participants Treated with Sotorasib

Description:

Adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and previously treated with at least 1 prior systemic therapy that have received sotorasib treatment in either location of BOAO Pilot Zone and Hong Kong SAR will be included in this cohort. The duration of evidence collection is from initiation of sotorasib to the end of study period, up to approximately 4 years from the date of the first available sotorasib use in BOAO Pilot Zone of around August 2021.

Treatment:

Drug: Sotorasib